Li Zhaoming, Qiu Ran, Qiu Xia, Tian Tian
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wuhan Institute of Bioengineering, Wuhan, China.
Oncotarget. 2017 Dec 2;8(67):110837-110848. doi: 10.18632/oncotarget.22860. eCollection 2017 Dec 19.
Lung cancer is the leading cause of cancer-related death worldwide. Despite advances have been made in diagnosis and therapeutic strategies, the prognosis of lung cancer is still very poor. Eyes absent transcriptional cofactor EYA2 has been shown to promote lung cancer cell growth, however, the underlying molecular mechanism is still not fully understood. In the present study, we found that EYA2 was up-regulated in lung cancer, and EYA2 led to increased cell proliferation by inhibiting Phosphatase and tensin homologue (PTEN) expression via modulation of miR-93. Additionally, survival analysis showed that lung cancer patients with higher EYA2 expression predicted a worse prognosis. Therefore, these findings demonstrate that EYA2 may play an important role in lung cancer occurrence and progression. Targeting EYA2 may provide a feasible approach in developing novel anticancer therapeutics.
肺癌是全球癌症相关死亡的主要原因。尽管在诊断和治疗策略方面取得了进展,但肺癌的预后仍然很差。无眼转录辅因子EYA2已被证明可促进肺癌细胞生长,然而,其潜在的分子机制仍未完全阐明。在本研究中,我们发现EYA2在肺癌中上调,并且EYA2通过miR-93调节抑制磷酸酶和张力蛋白同源物(PTEN)的表达,从而导致细胞增殖增加。此外,生存分析表明,EYA2表达较高的肺癌患者预后较差。因此,这些发现表明EYA2可能在肺癌的发生和发展中起重要作用。靶向EYA2可能为开发新型抗癌疗法提供一种可行的方法。